MX2019007684A - Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. - Google Patents
Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.Info
- Publication number
- MX2019007684A MX2019007684A MX2019007684A MX2019007684A MX2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- atom
- acceptable
- salt
- view
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto representado por la Fórmula general (1) a continuación o una sal de este aceptable desde el punto de vista farmacológico: (Ver Fórmula) en la Fórmula (1), R1 y R2 pueden ser iguales o diferentes, y cada uno representa un átomo de hidrógeno, un átomo de alógeno, un grupo hidroxilo, un grupo carboxi, un grupo ciano, un grupo C1-6 alquilo opcionalmente sustituido et al.; R3 representa un átomo de hidrogeno; R4 representa un grupo heterocíclico monocíclico opcionalmente sustituido de 4 a 10 miembros que contiene 1 a 4 heteroátomos seleccionados de un átomo de oxígeno, un átomo de nitrógeno y un átomo de azufre; X representa a un grupo representado por la fórmula siguiente: -CH2-, -CH2-CH2-, -CH2-CH2-CH2- o -CH2-O-CH2-; y Z representa un átomo de hidrogeno o un grupo hidroxilo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016251577 | 2016-12-26 | ||
| JP2017089251 | 2017-04-28 | ||
| PCT/JP2017/046610 WO2018124060A1 (ja) | 2016-12-26 | 2017-12-26 | 新規化合物及びその薬理的に許容される塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007684A true MX2019007684A (es) | 2019-09-09 |
| MX389276B MX389276B (es) | 2025-03-20 |
Family
ID=62709343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007684A MX389276B (es) | 2016-12-26 | 2017-12-26 | Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10669283B2 (es) |
| EP (1) | EP3560925B1 (es) |
| JP (1) | JP6815417B2 (es) |
| KR (1) | KR102414365B1 (es) |
| CN (1) | CN110114358B (es) |
| AU (1) | AU2017385199B2 (es) |
| CY (1) | CY1124643T1 (es) |
| DK (1) | DK3560925T3 (es) |
| ES (1) | ES2875548T3 (es) |
| HU (1) | HUE055468T2 (es) |
| IL (1) | IL267594B (es) |
| MX (1) | MX389276B (es) |
| PH (1) | PH12019501391A1 (es) |
| PL (1) | PL3560925T3 (es) |
| PT (1) | PT3560925T (es) |
| RU (1) | RU2767878C2 (es) |
| TW (1) | TWI752141B (es) |
| UA (1) | UA124353C2 (es) |
| WO (1) | WO2018124060A1 (es) |
| ZA (1) | ZA201904241B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021155336A (ja) * | 2018-06-27 | 2021-10-07 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 新規ｐｄｅ４阻害剤 |
| AR114977A1 (es) | 2018-06-27 | 2020-11-11 | Meiji Seika Pharma Co Ltd | Cristales de derivado de benzoxazol |
| KR20210024563A (ko) * | 2018-06-27 | 2021-03-05 | 메이지 세이카 파루마 가부시키가이샤 | 염증성 질환, 자가면역 질환, 섬유화 질환 및 암 질환의 치료제 |
| PH12021552733A1 (en) | 2019-04-30 | 2023-01-16 | Aicuris Gmbh & Co Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
| CN111057075B (zh) * | 2019-12-24 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | Ret抑制剂及其制备方法 |
| IL309736A (en) * | 2021-06-30 | 2024-02-01 | Meiji Seika Pharma Co Ltd | A method for producing a derivative of benzoxazole having a bicyclic piperazine ring or a salt thereof and a method for producing a substance from it |
| CN116283813B (zh) * | 2023-01-18 | 2025-07-08 | 南方医科大学 | 苯并恶唑类化合物或其药学上可接受的盐、水合物、n-氧化合物或溶剂合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61166827A (ja) | 1985-01-17 | 1986-07-28 | Toray Ind Inc | 変性エポキシ系微粒子 |
| JP3193560B2 (ja) * | 1993-04-16 | 2001-07-30 | 明治製菓株式会社 | 新規ベンゾオキサゾール誘導体 |
| JP3520177B2 (ja) | 1996-05-09 | 2004-04-19 | 明治製菓株式会社 | セロトニン５−ｈｔ３受容体部分活性薬 |
| GB0003256D0 (en) * | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
| BR0314485A (pt) * | 2002-09-25 | 2005-07-26 | Memory Pharm Corp | Indazóis, benzotiazóis e benzoisotiazóis, composto, composição farmacêutica, método desativação/estimulação seletiva de receptores nicotìnicos de a-7 em um mamìfero e método de tratamento e/ou prevenção de uma doença com os mesmos |
| US7307094B2 (en) * | 2005-02-17 | 2007-12-11 | Amr Technology, Inc. | Benzoxazole carboxamides for treating CINV and IBS-D |
| NZ574756A (en) * | 2006-08-07 | 2011-03-31 | Albany Molecular Res Inc | 2-aminobenzoxazole carboxamides as 5ht3 modulators |
| US8486948B2 (en) | 2007-10-19 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Piperazinodihydrothienopyrimidine derivatives |
| CN105431427B (zh) * | 2013-07-10 | 2017-12-08 | 明治制果药业株式会社 | 新型pde4 抑制剂 |
-
2017
- 2017-12-26 AU AU2017385199A patent/AU2017385199B2/en active Active
- 2017-12-26 HU HUE17885917A patent/HUE055468T2/hu unknown
- 2017-12-26 PT PT178859179T patent/PT3560925T/pt unknown
- 2017-12-26 DK DK17885917.9T patent/DK3560925T3/da active
- 2017-12-26 WO PCT/JP2017/046610 patent/WO2018124060A1/ja not_active Ceased
- 2017-12-26 UA UAA201908271A patent/UA124353C2/uk unknown
- 2017-12-26 CN CN201780080389.7A patent/CN110114358B/zh active Active
- 2017-12-26 JP JP2018559513A patent/JP6815417B2/ja active Active
- 2017-12-26 EP EP17885917.9A patent/EP3560925B1/en active Active
- 2017-12-26 PL PL17885917T patent/PL3560925T3/pl unknown
- 2017-12-26 KR KR1020197021334A patent/KR102414365B1/ko active Active
- 2017-12-26 MX MX2019007684A patent/MX389276B/es unknown
- 2017-12-26 TW TW106145711A patent/TWI752141B/zh active
- 2017-12-26 ES ES17885917T patent/ES2875548T3/es active Active
- 2017-12-26 RU RU2019122999A patent/RU2767878C2/ru active
- 2017-12-26 US US16/473,507 patent/US10669283B2/en active Active
-
2019
- 2019-06-18 PH PH12019501391A patent/PH12019501391A1/en unknown
- 2019-06-23 IL IL267594A patent/IL267594B/en unknown
- 2019-06-27 ZA ZA2019/04241A patent/ZA201904241B/en unknown
-
2021
- 2021-09-01 CY CY20211100780T patent/CY1124643T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3560925T3 (da) | 2021-06-28 |
| US20190322686A1 (en) | 2019-10-24 |
| ZA201904241B (en) | 2020-12-23 |
| AU2017385199B2 (en) | 2021-09-09 |
| MX389276B (es) | 2025-03-20 |
| TW201835080A (zh) | 2018-10-01 |
| EP3560925A4 (en) | 2020-06-10 |
| ES2875548T3 (es) | 2021-11-10 |
| CN110114358B (zh) | 2021-12-03 |
| AU2017385199A1 (en) | 2019-07-04 |
| CA3048170A1 (en) | 2018-07-05 |
| PT3560925T (pt) | 2021-07-28 |
| WO2018124060A1 (ja) | 2018-07-05 |
| EP3560925A1 (en) | 2019-10-30 |
| PL3560925T3 (pl) | 2021-12-20 |
| EP3560925B1 (en) | 2021-06-02 |
| BR112019010571A2 (pt) | 2019-09-17 |
| JPWO2018124060A1 (ja) | 2019-10-31 |
| RU2019122999A (ru) | 2021-01-26 |
| CY1124643T1 (el) | 2022-11-25 |
| RU2767878C2 (ru) | 2022-03-22 |
| NZ754689A (en) | 2024-04-26 |
| UA124353C2 (uk) | 2021-09-01 |
| HUE055468T2 (hu) | 2021-11-29 |
| IL267594B (en) | 2022-04-01 |
| RU2019122999A3 (es) | 2021-03-31 |
| PH12019501391A1 (en) | 2020-02-10 |
| CN110114358A (zh) | 2019-08-09 |
| KR20190097235A (ko) | 2019-08-20 |
| KR102414365B1 (ko) | 2022-07-01 |
| JP6815417B2 (ja) | 2021-01-20 |
| TWI752141B (zh) | 2022-01-11 |
| US10669283B2 (en) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007684A (es) | Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| ECSP10010060A (es) | Derivados de pirazol sustituídos | |
| DK2091948T3 (da) | Nye inhibitorer af glutaminylcyclase | |
| AR055144A1 (es) | Inhibidor de secrecion acida | |
| CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| CO6361916A2 (es) | Compuestos de isoindolina para uso en el tratamiento | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| ECSP11010946A (es) | Nuevos compuestos heterocíclicos nitrogenados, preparación de los mismos y utilización de los mismos como medicamentos antibacterianos | |
| CO6361934A2 (es) | Composicion farmaceutica solida | |
| AR090091A1 (es) | Sulfin- y sulfonimidoilbenzamidas de accion herbicida | |
| NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
| PH12017501655B1 (en) | Morphinan derivative | |
| MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
| MX2018011721A (es) | Compuesto de griseofulvina. | |
| AR089297A1 (es) | Uso de derivados de diamida antranilicos con sustituyentes heteroaromaticos y heterociclicos en combinacion con un agente de control biologico | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO6251285A2 (es) | Derivado de tetrahidroisoquinolina novedoso |